ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it is partnering with the Critical Path Institute (“C-Path”) to develop a physiologically-based pharmacokinetic (PBPK) model of the human lung. Built to work in conjunction with Certara’s Simcyp™ Population-based Simulator, the model will be used to predict the disposition of drugs within the lungs and the potential impact of disease-progression on drug kinetics at different stages of tuberculosis (TB) infection.
Help employers find you! Check out all the jobs and post your resume.
